Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to emulate, as closely as is possible in healthcare insurance claims data, the EMPEROR-Reduced trial described below. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization cannot be achieved in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for emulation for a range of possible reasons and does not provide information on the validity of the original RCT finding.
The EMPEROR-Reduced trial, was a superiority trial to evaluate the effect of Empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), versus placebo on the risk of cardiovascular death and hospitalisation for heart failure among individuals with chronic heart failure with reduced ejection fraction.
The database study is designed to emulate EMPEROR-Reduced. It will be a new-user comparative cohort study, conducted using 3 national United States claims databases comparing the effect of empagliflozin versus sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP4i), on all-cause mortality and hospitalisation for heart failure. While the EMPEROR-Reduced trial compared empagliflozin to placebo, use sitagliptin was chosen as an active comparator proxy for placebo to minimize confounding by indication sitagliptin was specifically chosen because a major randomized controlled trial on cardiovascular outcomes demonstrated that it does not affect the cardiovascular outcomes under investigation. Furthermore, clinical guidelines during the study period recommended both SGLT2 inhibitors and DPP4 inhibitors as second- or third-line options for glucose lowering, and the therapies are similarly costly, reducing concerns about channelling of patients based on socioeconomic status.
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02120
- Brigham and Women's Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Optum: Study period between 1st August 2014 - 31st December 2024. Marketscan: Study period between 1st August 2014 - 30th September 2022. Medicare: Study period between 1st August 2014 - 30th September 2022.
Inclusion Criteria:
- At least 18 years of age
- Heart failure with reduced ejection fraction
- Type 2 diabetes mellitus
- Use of oral diuretics
- Use of appropriate medical therapy for HF
Exclusion Criteria:
- Concurrent use of both study drugs on cohort entry date
- MI, CABG or other major cardiovascular surgery, GI surgery or disorder, stroke or TIA
- Implantable cardiac defibrillator
- Hypotension
- Major surgery
- GI surgery or disorder
- Cancer
- Heart transplant
- LVAD
- Liver disease
- Atrial fibrillation
- Hypertension
- Impaired renal function
- Anemia
- Ketoacidosis
- Pregnancy
- Ventricular arrhythmia
- Heart block
- Cardiomyopathy
- Valvular heart disease
- Chronic pulmonary disease
- Combined comorbidity score
- Chronic alcohol and or drug abuse
- Noncompliance
- Acute decompensated HF
- Use of SGLT2i or DPP4i
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
시타글립틴
참조 그룹
|
Initiation of sitagliptin described in electronic health records is used as the reference.
|
|
엠파글리플로진
노출 그룹
|
Initiation of empagliflozin described in electronic health records is used as the exposure.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to first occurrence of hospitalization for heart failure or all-cause mortality
기간: From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
The primary outcome is the time from 1 day after cohort entry to the first occurrence of either component of the composite endpoint: hospitalization for heart failure or all-cause mortality, comparing empagliflozin versus sitagliptin in patients with chronic heart failure and reduced ejection fraction.
|
From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to first occurrence of cataract surgery
기간: From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
The outcome is the time from 1 day after cohort entry to the first occurrence of cataract surgery as a negative control outcome, comparing empagliflozin versus sitagliptin.
|
From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
|
Time to first occurrence of lumbar radiculopathy
기간: From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
The outcome is the time from 1 day after cohort entry to the first occurrence of lumbar radiculopathy as a negative control outcome, comparing empagliflozin versus sitagliptin.
Patients with a recent occurrence of lumbar radiculopathy before the follow-up time window are excluded using a 30-day lookback period.
|
From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
|
Time to first occurrence of hernia
기간: From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
The outcome is the time from 1 day after cohort entry to the first occurrence of hernia as a negative control outcome, comparing empagliflozin versus sitagliptin.
Patients with a recent occurrence of hernia before the follow-up time window are excluded using a 30-day lookback period.
|
From 1 day after entry through first occurrence of outcome, disenrollment, end of study period, treatment discontinuation +45-day grace/risk window, treatment switch, nursing home admission, or start of other SGLT2i or DPP4i, assessed up to 1 year.
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Shirley Wang, PhD, ScM, Brigham and Women's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2018P002966-EMPERORReduced
- 75F40122C00154 (기타 보조금/기금 번호: Food and Drug Administration)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .